David Bouchey
Stock Analyst at Aegis Capital
(n/a)
# 4,407
Out of 4,761 analysts
7
Total ratings
n/a
Success rate
-55.75%
Average return
Main Sectors:
Stocks Rated by David Bouchey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SBFM Sunshine Biopharma | Reiterates: Buy | $15 | $2.45 | +512.24% | 2 | Dec 5, 2024 | |
| STSS Sharps Technology | Initiates: Buy | $352 | $0.36 | +98,776.40% | 1 | May 9, 2023 | |
| ATXI Avenue Therapeutics | Initiates: Buy | $2,400 | $1.36 | +176,370.59% | 1 | Apr 3, 2023 | |
| IINN Inspira Technologies Oxy B.H.N. | Maintains: Buy | $10 → $13 | $0.87 | +1,391.51% | 1 | Jan 25, 2023 | |
| RMTI Rockwell Medical | Downgrades: Outperform | $121 | $1.77 | +6,736.16% | 2 | Oct 19, 2018 |
Sunshine Biopharma
Dec 5, 2024
Reiterates: Buy
Price Target: $15
Current: $2.45
Upside: +512.24%
Sharps Technology
May 9, 2023
Initiates: Buy
Price Target: $352
Current: $0.36
Upside: +98,776.40%
Avenue Therapeutics
Apr 3, 2023
Initiates: Buy
Price Target: $2,400
Current: $1.36
Upside: +176,370.59%
Inspira Technologies Oxy B.H.N.
Jan 25, 2023
Maintains: Buy
Price Target: $10 → $13
Current: $0.87
Upside: +1,391.51%
Rockwell Medical
Oct 19, 2018
Downgrades: Outperform
Price Target: $121
Current: $1.77
Upside: +6,736.16%